How to Prevent the Common Mistakes Business Owners Make

How to Prevent the Common Mistakes Business Owners Make


How to Prevent the Common Mistakes Business Owners Make

According to a statistic by the U.S. Bureau of Labor, more than 18% of new businesses fail during their first two years of operation, and about 55 percent of all businesses do not survive past their fifth year. So how do you successfully launch and run your business?

1. Taking the Time to Plan

A frequent issue in start-up businesses is diving straight into opening the business. However, taking the time to plan will help to ensure that your business starts on the right foot. Taking the time to do your research and due diligence can give you a great foundation for success when opening your business’ doors.

Before starting a business, it is a good idea to:

  • Do market research
  • Create a business plan
  • File for the proper legal structure
  • Buy the right type of business insurance

Furthermore, all start-up businesses should map out a business plan that includes: how much it costs to operate, an estimated revenue, and who would buy the product- or service- and why.

2. Finding Trustworthy Advisors

Another big mistake which entrepreneurs make is thinking that they are able to do everything on their own by not surrounding themselves with wise counsel. It is crucial to find and onboard trustworthy advisors who will discuss business ideas, strategies, challenges, and progress.

Five recommended consultative services include:

  • A banking relationship
  • A legal relationship
  • An accounting relationship
  • An insurance relationship
  • An individual who will be your advocate and consultant

3. Forming Contracts

Relying only on verbal or handshake agreements is one of the most common business mistakes and is a predictable source of legal problems.

If you would like your business to run smoothly, it is important that you create a clear, professionally written contract with all your:

  • Employers
  • Vendors
  • Investors
  • Employees

Moreover, contracts help to protect all parties involved in the agreement; so, do not feel reluctant to ask for things to be put in writing.

4. Marketing and Advertising

There is only so much that a business can accomplish by word-of-mouth. Business Owners can lose out on potential customers and revenue if they do not have a marketing plan or advertise their company.

When it comes to marketing for businesses, a great place to start is social media. You can create a business profile on different platforms and use them to promote your business. Content can consist of posts such as a behind-the-scenes look at running the business or offering giveaways and promotions. Social media is an easy way to broaden your network of customers.

In addition, make sure that you are familiar with the federal regulations that are related to marketing and advertising. For instance, you could violate a Federal Trade Commission (FTC) regulation if you unintentionally send out a newsletter to someone who requested to opt out of the mailing list.

Creating a thorough business plan, having the right advisors on your team, being strategic about hiring, and advertising your business are some of the important steps towards successfully running a business.

Sources:

https://www.bls.gov/bdm/us_age_naics_00_table7.txt

https://www.businessnewsdaily.com/7398-startup-mistakes-to-avoid.html

https://www.thehartford.com/business-insurance/strategy/small-business-mistakes/common-mistakes

The post How to Prevent the Common Mistakes Business Owners Make appeared first on Connor & Connor PLLC.

Source link

Americans Are Still Saying “Yes, Please!” to Cannabis Legalization

Americans Are Still Saying “Yes, Please!” to Cannabis Legalization

Americans Are Still Saying “Yes, Please!” to Cannabis Legalization

A new 2025 YouGov survey involving over 31,000 U.S. adults reveals overwhelming support for both recreational and medical cannabis legalization across the country. Americans are also strongly in favor of federal cannabis reform, which would allow for crucial banking access, expanded research, and interstate commerce. This consistent public demand signals a likely continuation of the green wave in policy and markets.

It seems like every other day, we’re seeing headlines about cannabis legislation shifting, new states going green, and the industry booming. But what do everyday Americans really think about it all? Well, a massive 2025 YouGov survey involving over 31,000 U.S. adults has just dropped, and the message is crystal clear: the vast majority are still waving their “legalize it!” flags high.

The Green Light is On: Recreational and Medical Cannabis Wins

Remember when talking about cannabis felt a bit taboo? Those days are rapidly fading into the rearview mirror. The YouGov data shows significant, widespread support for both recreational and medical cannabis use. And honestly, are we surprised? The benefits of medical cannabis are becoming increasingly undeniable, offering relief for everything from chronic pain to anxiety. For recreational use, it’s often less about escaping reality and more about adult enjoyment – just like a glass of wine after a long day.

Think about it: as more states successfully implement regulated adult-use markets, the scare tactics of the past just don’t hold up. Tax revenues are boosting state budgets, new jobs are being created, and consumers have safer, tested products. It’s hard to argue with tangible, positive outcomes, right?

Beyond State Lines: The Push for Federal Reform

While state-level changes are fantastic, the big kahuna is federal legalization. And guess what? Americans are overwhelmingly on board here too. This isn’t just about convenience for consumers; federal reform would unlock a cascade of benefits for the entire cannabis industry and beyond.

Why Federal Reform Matters (A Lot!)

  • Banking Access: Imagine running a multi-billion dollar industry that still struggles with basic banking services! Federal decriminalization would allow cannabis businesses to access traditional banks, loans, and credit card processing, operating like any other legitimate sector. No more suitcases full of cash, hopefully!
  • Research Opportunities: Our understanding of the cannabis plant’s full potential – both therapeutic and otherwise – is still relatively nascent thanks to federal prohibition. Rescheduling or descheduling would dramatically open up research opportunities, allowing scientists to study cannabis without the current bureaucratic hurdles.
  • Interstate Commerce: Currently, cannabis grown in Oregon can’t legally be sold in California, even if there’s a demand. Federal reform would pave the way for interstate commerce, creating a more efficient and competitive national market.
  • Social Equity: Federal action could also address the historical injustices of the War on Drugs, providing pathways for expungement of past convictions and supporting entrepreneurship in communities disproportionately affected.

What Does This Mean for the Future of Cannabis?

This robust support isn’t just a flicker; it’s a consistent flame indicating that cannabis legalization is not a fad, but a societal shift. It tells policymakers that they’re lagging behind public opinion if they’re not actively pursuing reform.

We’re witnessing a fascinating evolution in perception, where cannabis is increasingly viewed through a lens of health, wellness, and personal liberty rather than moral panic. The data speaks volumes: Americans are ready for a fully legal, well-regulated cannabis landscape from coast to coast.

So, grab your favorite herbal tea (or, you know, something else if you’re in a legal state!), because the future looks decidedly green.

Source link

France’s Budget Chaos Nears Resolution, Removing Major Barrier for Medical Cannabis Rollout

France’s Budget Chaos Nears Resolution, Removing Major Barrier for Medical Cannabis Rollout

France’s Budget Chaos Nears Resolution, Removing Major Barrier for Medical Cannabis Rollout

Earlier this week (Tuesday, January 27), France’s government survived two no-confidence votes, finally passing its contentious 2026 budget following months of political crisis that had largely paralysed non-urgent policymaking.

The budget crisis, which forced Prime Minister Sébastien Lecornu, against its inital wishes, to invoke Article 49.3 of the Constitution three separate times to ram through fiscal plans without the necessary parliamentary votes, now appears to be nearing a resolution. 

For France’s incoming medical cannabis industry, the budget resolution will remove a major obstacle. The regulatory texts governing France’s permanent framework have sat complete and validated since August 2025, awaiting only ministerial signatures, signatures that health officials have been unable to prioritise amid the fiscal chaos.

“The main (blocker) is the budget negotiations that have been dragging on,” Benjamin-Alexandre Jeanroy, CEO of Paris-based consultancy Augur Associates, told Business of Cannabis. “Once that is settled, which should happen around mid-February, then we’ll hopefully have a month and a half before the end of Q1 to finally close the process.”

A second political distraction has also now cleared. Health Minister Stéphanie Rist, who must sign the medical cannabis texts alongside the Minister of Economy, was simultaneously forced to campaign in a high-stakes by-election in Loiret after her deputy replacement refused to take her spot at the National Assemblé once she got nominated in the government. 

She won decisively on January 25 with 62.1% of the vote, eliminating what Jeanroy describes as another attention-draining factor. “Some of the lingering files can now be taken seriously, hopefully”, he suggests.

Cannabis Europa Paris

Companies are building dossiers despite political delays

While progress now looks more promising, the industry-in-waiting still has little clarity on when the bill will be signed and published in the Journal Officiel. 

However, thanks to medical cannabis being integrated into France’s existing pharmaceutical framework, there is plenty of clarity on what needs to be done in preparation, meaning companies can hit the ground running whenever that day comes. 

“Even if today you cannot submit a dossier, you can prepare everything that’s needed,” Jeanroy explains. “We know at 99% what’s going to be needed in it, to the specific format they’re asking for, and with all the components that’s needed.”

That preparation process involves two critical steps. First, companies must secure an ‘exploitant pharmaceutique’ partner, a French pharmaceutical entity licensed to handle the regulatory filing, distribution, and pharmacovigilance required under France’s system. 

“There are two main tasks that you need to do. The first one is to find your exploitant partner. And that defines a lot of other stuff that you need or don’t need to do directly in-house afterwards, including the product registration, which is the second step.”

The second step is assembling the pharmaceutical dossier itself, a comprehensive file demonstrating EU GMP compliance, product stability, safety data, and manufacturing standards. 

“The process is a bit tough and pharmaceutical,” Aurélien Bernard, co-founder of industry publication Newsweed, told Business of Cannabis. “It implies a lot of documents needed, and it’s a bit expensive too.”

Companies that have been working on these partnerships and dossiers over the past year, while the regulatory texts sat in political limbo, are positioning themselves for faster market entry once publication occurs. “All the companies that are doing that prior to the signing of the decree and the opening of the submission phase are taking advantage,” Jeanroy says.

Previously, we reported that industry insiders had estimated products could take anywhere from eight to 11 months to hit pharmacy shelves after publication. However, both Jeanroy and Bernard believe the well-trodden framework will significantly expedite this timeline. 

Streamlined roll-out

The official ANSM timeline for pharmaceutical product authorisation is around three months for standard approvals, according to Jeanroy. For more complex or innovative formulations, that period could be stretched.  

“The official timeline is 90 days,” Jeanroy says. “It could realistically be doubled for an innovative form for medical cannabis, which is most of the forms except the oil.”

That puts the upper end of the approval process at six months for novel delivery methods. However, because oils have been a prominent part of France’s pilot medical cannabis access scheme, the ANSM already has years of experience managing this type of product, meaning it could move considerably faster. 

For companies with experienced pharmaceutical consultants who understand both ANSM processes and medical cannabis complexity, the timeline compresses further. “I think the answer is probably more in three to six months,” Jeanroy estimates, with a further two months for production, organisation and packaging approval potentially being added. 

For straightforward oil formulations from companies with strong pharmaceutical partnerships, the journey from publication to pharmacy shelves could be completed in as little as five months.

“If you have people on your side that have experience with registration, obviously elsewhere on medical cannabis products, and people in France that have experience not only in prior registration with the ANSM, but also ideally with medical cannabis, because we know how complex that is, that’s a good position to be in,” Jeanroy notes.

The reimbursement question 

As Curaleaf International’s CEO, Juan Martinez, told us recently, the ‘higher regulatory and manufacturing standards’ of this market make cost a ‘legitimate concern… especially before reimbursement pathways exist’. 

Deputy Galliard-Minier’s warning that medical cannabis could remain ‘inaccessible for many patients’ without proper pricing and reimbursement speaks to a genuine concern. France’s Haute Autorité de Santé (HAS) will ultimately determine both pricing structures and reimbursement rates, decisions that could prove more consequential than the regulatory timeline itself.

“Theoretically, those conditions are long-term afflictions, and so they should fall under the 100% reimbursement scheme rate,” Jeanroy explains. Patients with refractory neuropathic pain, drug-resistant epilepsy, or other qualifying conditions already receive full reimbursement for conventional medications. “So all those people, they are taking this medication for life… they need the drugs. In an expected setting, they should be reimbursed 100%.”

But budget reality may override theoretical logic. “However, budget reality is a fact, and it has probably been an impediment to the generalisation of the framework,” he notes. “The solution is probably going to be something midway.”

Jeanroy’s estimate that realistically reimbursement should be between 30% and 60%, with 30% representing ‘the minimum under which it would be shameful’ and 60% being ‘more accurate, because it’s usually what anxiolytics are being reimbursed for.’ 

HAS has already received preliminary dossiers from companies preparing products, and its evaluation process should conclude by the end of Q1 2026, assuming the decree is published first. But timing once again becomes critical, as HAS cannot finalise its work without the published decree.

“What they cannot do is interact with third parties. All the additions that they wanted to do, all those things that are external to the HAS, they cannot act on them because of the lack of the decree.”

Jeanroy suggests HAS will likely set prices based on two criteria, product form (oil, capsule, etc.) and THC/CBD ratio, rather than evaluating each product individually.

“The first dossier would be an oil at, for example, 50/50, and they would give a price point of, let’s say, €20 a bottle. And that means that tomorrow, if you have another product or another company that comes in with an oil with that ratio, it’s probably going to be that price point.”

With France’s budget crisis now appearing to be resolved, and its Health Minister freed from electoral distractions, the medical cannabis industry awaits what many hope will be the swift publication of the long-delayed regulatory texts. 

 

The remaining questions, set to significantly influence the ultimate form of the sector, will be examined at Cannabis Europa Paris on February 19, where industry leaders, policymakers, and healthcare professionals will gather to assess France’s transition from pilot programme to permanent framework. 

The post France’s Budget Chaos Nears Resolution, Removing Major Barrier for Medical Cannabis Rollout appeared first on Business of Cannabis.

Source link

Avocados vs Bombs: How Legal Cannabis Markets Beat the Cartels Without Firing a Shot

Avocados vs Bombs: How Legal Cannabis Markets Beat the Cartels Without Firing a Shot

Avocados vs Bombs: How Legal Cannabis Markets Beat the Cartels Without Firing a Shot

So if the prohibitionist logic holds—if consumer purchases fund violence—then every millennial posting #plantbased avocado toast on Instagram is directly funding organizations that murder people, destroy forests, drain aquifers, and corrupt governments. But here’s what’s fascinating: nobody’s proposing we bomb Michoacán’s avocado farms or launch a “War on Avocados.”

Source link

Zen Durian Ranger Strain Feminized Seeds

Zen Durian Ranger Strain Feminized Seeds

Zen Durian Ranger Strain Feminized Seeds

Description

Zen Durian Ranger produces eye-catching buds that highlight the best traits of its legendary parents. The aroma is complex, beginning with a strong chemical and diesel scent that commands attention. As you exhale, a deep, earthy base provides a spicy finish that lingers on the tongue. The effects kick in fast, offering a quick mental boost that clears the mind and sparks creativity. Over time, that energy blends into a soothing body sensation that helps manage stress. This balance lets you stay productive and happy without feeling heavy or tired.

The post Zen Durian Ranger Strain Feminized Seeds appeared first on Crop King Seeds.

Source link

Corporate Transparency Act (CTA)

Corporate Transparency Act (CTA)

Corporate Transparency Act (CTA)

As the end of 2024 quickly approaches, it is imperative for companies and business owners to report their beneficial ownership information for all entities subject to the Corporate Transparency Act before the January 1, 2025, deadline.

The Corporate Transparency Act (CTA) came into effect on January 1, 2024, representing a significant shift towards increasing transparency in business ownership and combating illicit financial activities. The supposed purpose of the CTA is to address issues related to money laundering, tax evasion, fraud, and other financial crimes. The unfortunate side effect has been to sweep up the vast majority of honest small business owners in the broad net created by the CTA.

Key terms contained within the CTA include:

  • Reporting Company: most entities formed in or registered to do business in the United States will fall under this term. However, the act also creates numerous exemptions, which exclude certain categories of entities.
  • Beneficial Owner: any individual who (i) owns 25% or more of a reporting company or (ii) exercises “substantial control” over a reporting company. Additionally, many senior executives (e.g. company presidents, chief financial officers, general counsel, chief executive officers, or any other officer who performs a similar function) will be deemed beneficial owners under the CTA due to their control over a reporting company.
  • Company Applicant: an individual who directly files an entity’s formation documents with a relevant state or tribal authority or, if more than one person is involved in the filing, the individual primarily responsible for directing or controlling the filling.

The CTA and regulations promulgated by the U.S. Department of Treasury, will require nearly all small businesses in the United States to file reports with the Financial Crimes Enforcement Network (FinCEN). Specifically, all reporting companies will be required to report various information to FinCEN about the Reporting Company and their Beneficial Owners. If Reporting Companies were formed on or after January 1, 2024, each new Reporting Company is required to file their initial report with FinCEN, within ninety days following the company’s formation. If a Reporting Company was formed before January 1, 2024, but prior to January 1, 2025, the deadline to file their initial report with FinCEN before January 1, 2025. However, considering the recent hurricane, certain companies qualify for a six-month extension period. Lastly, for all Reporting Companies, if there is any change in the information that was reported previously by the Reporting Company, an updated report must be filed within thirty days of the change.

When preparing to file a report either using a Form FinCEN114, or reporting directly online via FinCen’s website, it is important to consult the FinCEN regulations and instructions to ensure accuracy and completeness. The form necessitates various details about Beneficial Owners including full name, date of birth, residential or business address, and a unique identification number (e.g. a social security number for U.S. citizens or a passport for non-U.S. citizens). Further, the form may require information about any intermediary owners, such as trusts, which hold ownership on behalf of another entity.

If a Reporting Company fails to report complete or updated Beneficial Ownership information to FinCEN or attempts to provide false or fraudulent Beneficial Ownership information, the company may face civil or criminal penalties. Also, a person may be subject to civil or criminal penalties for causing a reporting company not to file a required BOI Report or to report incomplete or false Beneficial Ownership information.

The CTA applies to a broad range of entities, including corporations, limited liability companies (LLCs), and other similar entities, which are formed or registered in the United States. It is important to note that there are 23 exemptions from the CTA. Therefore, the organizations which qualify for an exemption are not subject to the CTA’s reporting requirements. For more information on if your company qualifies for a CTA exemption, it is important to undergo comprehensive legal and regulatory review to ensure your company is exempt from the CTA reporting requirements. If you are in need of expert business attorneys to review the CTA exemptions for your company, give Connor & Connor PLLC a call for a consultation today!

The post Corporate Transparency Act (CTA) appeared first on Connor & Connor PLLC.

Source link

party drug testing

Government-Led Party Drug-Testing: Inside Uruguay’s No-Penalty Harm Reduction Program

Government-Led Party Drug-Testing: Inside Uruguay’s No-Penalty Harm Reduction Program

Far from demonizing people who use drugs—a global reality that some countries have chosen to acknowledge and address rather than forbid—Uruguay is joining an initiative that has already proven successful: testing drugs at parties, raves, and festivals, according to El Debate.

Uruguay’s National Drug Board (Junta Nacional de Drogas, JND), part of the Executive Branch, has launched a program to fund the analysis of some of the most commonly used drugs in the country’s nightlife scene over the course of 2026. The goal is to identify the chemical components of illegal drugs that attendees voluntarily submit for testing, in collaboration with the harm reduction organization Imaginario9.

Put simply: without punishment or snitching, people who attend these events and carry substances—such as MDMA, LSD, or cocaine—will be able to access concrete information about what they bought, allowing them to make more responsible decisions.

The State’s responsibility in drug use

Harm reduction could be part of any country’s public policy framework—in fact, some states have started moving in this direction.  This time, it’s Uruguay that has begun to recognize its responsibility here. But the State isn’t doing so alone.

Imaginario9, a civil society collective made up of chemists, lawyers, psychologists, sociologists, and professionals from other disciplines—all postgraduate students in drug policy at the University of the Republichas aligned with the JND to help ensure safer experiences for people who use drugs at parties.

This is not the first time drug testing has taken place at events and through harm-reduction interventions in Uruguay. Early precedents include voluntary pill-testing initiatives carried out at events in 2016. At the time, local NGOs worked with the support of specialized harm reduction groups such as Proderechos and Energy Control, a leading Spain-based organization.

Thanks to the interdisciplinary work of these professionals—and a significant donation of reagents and equipment that made it possible to assemble the mobile laboratory Imaginario9 uses today—135 samples of synthetic drugs were analyzed, and several turned out to be adulterated.

That first intervention helped pave the way, albeit without state involvement. This is where the current shift becomes clear: for the first time, the Uruguayan state is formally inviting civil society groups—and funding the work systematically—through a public call to carry out drug testing across multiple events.

When State and civil society work together

Imaginario9 has been part of the Early Warning System (Sistema de Alerta Temprana, SAT) for years—a fact that, according to the organization, shows that their work “is useful and that the State coordinator considers the information we provide to be valuable.” As a result, Imaginario9 secured State funding through a public call issued late last year.

This opportunity arose after the government issued a call for civil society organizations already conducting interventions at parties and nightlife venues, including substance testing. The explicit goal was for organizations to submit proposals incorporating harm reduction strategies, reliable drug information, collective care, and peer-to-peer guidance in recreational settings.

Several proposals were submitted, and the contract was ultimately awarded to Imaginario9. Other organizations involved in the evaluation process included the Uruguayan Red Cross, Espacio Kablam, Montblanc, Coopetca, and Casa Ambiental de Castillos, underscoring the initiative’s intent to work alongside a diverse range of specialized social actors.

That way, after being selected to run the program, the group committed to carrying out interventions at six mid-sized parties (500–800 people), three large parties (over 1,000 people), and three additional activity-based sessions throughout 2026. “A very important challenge for us,” they say, “and one that gives us the chance to bring some regularity to our work, which has always been volunteer-driven, run on sheer effort”.

Along those same lines, Florencia, a political scientist from the University of the Republic with a postgraduate diploma in Drug Policy, Regulation, and Control, brings a perspective that expands the public health lens into the realm of human rights. With more than a decade of experience in social organizations focused on drug policy and harm reduction, she explains that Imaginario9’s work goes beyond substance testing: “We also work to expand and defend the human rights of people who engage with drugs, with the goal of building articulation and advocacy efforts to reform prohibitionist drug policy.”

From that perspective, Harm Reduction and Pleasure Management also means mitigating the harms produced by repressive policies themselves, questioning drug policy through gender, generational, and intersectional lenses, and confronting the processes of stigmatization, discrimination, and criminalization that affect both people who use drugs and those who become entangled in low-level trafficking dynamics.

“We denounce the consequences that the application of punitive criminal laws and repression have on the social fabric of our communities,” she notes.

Imaginario9 has been active since 2016, carrying out drug tests with varying frequency. Because the work has been volunteer-based, the pace and number of testing sessions and related activities have been limited by time availability. Usually, they manage to maintain at least four to six testing sessions per year (around one every two to three months). The project developed in collaboration with the JND, however, will provide more resources and allow for greater structure if higher frequency can be achieved.

According to a chart shared by the collective with El Planteo, the most recent testing dates were as follows:

Date Venue / Event Type of Space Number of Samples
10/31/2024 Keylloween (Key Producciones), Canelones Large-scale party (3,500 attendees), young audience 37
02/15/2025 Lunatik – Ciudad de la Costa, Canelones Mid-sized party (500 attendees), young adult audience 41
06/14/2025 Helium – LCLUB Mid-sized party (500 attendees), young audience 34
10/03/2025 Helium – Lotus Club Mid-sized party (500 attendees), young audience 39

 

Uruguay: The current state of adulterated drugs at parties

When we think about the volume of illegal drugs purchased globally, we must also consider the lack of information about what is actually being consumed.

As the Imaginario9 collective explains, the frequency with which people who test their substances discover that what they were sold is not, in fact, what they thought they bought is higher than they would like.

They note that “it varies greatly depending on the testing session, but in our reports we calculate an ‘adulteration index’ that generally falls between 30% and 60%,” adding that the highest levels of adulteration are found in cocaine compared to other substances.

Another key observation, according to the collective, is that prior to the 2020 pandemic, most of the analyzed samples did in fact turn out to be what they claimed to be. MDMA—whether in pill or crystal form—generally was MDMA, and adulteration rates were low. After 2020, however, the situation shifted, with the emergence of MDMA’s precursor and analog compound, MDA.

MDA’s effects are less empathogenic and more hallucinogenic, and it also takes longer to take effect. This often leads users to “redose quickly in search of the familiar empathogenic effects of ecstasy, at which point they may ‘overdo it,’ increasing the risk of intoxication.”

Pills containing amphetamines or caffeine have also been detected: these adulterants are quite common due to their stimulant effects, according to the organization. Users often describe this experience as a “rough comedown”, since it makes it much more difficult to fall asleep afterward.

When it comes to LSD, adulteration rates tend to be lower, although blotters are sometimes found to be adulterated with NBOMes, a synthetic phenethylamine with a higher toxicity risk.

Taken together, these findings show that illegality does not reduce drug use or guarantee public safety. Quite the opposite. People continue to purchase drugs on illicit markets without knowing what they are actually ingesting.

And what happens when we actually do know what we’re consuming?

Despite criticism often directed at these intervention spaces and at people who choose to consume anyway, drug testing at parties does not promote use. Rather, it prevents deaths—plain and simple—because when people learn that the substances they’re carrying are not what they thought they bought, they often choose to discard them.

“What happens many times is that people who receive a ‘negative’ result for their substance—that is, they learn it’s adulterated—decide to throw it away and not consume it. In that case, it’s a clear deterrent to use,Imaginario9 explains.

But when the situation is reversed, the equation doesn’t change much: the decision was already made. “In the opposite case, when someone receives a ‘positive’ result, that can’t be understood as promoting use either. A person who approaches a testing device with a pill in hand already made the decision to ingest it long before, back when they obtained the substance. The only difference now is that they have more information about it. And if we’ve done our job right, we also share safer-use practices that help prevent overdosing,” they add.

Drug testing works (and it has for a long time)

Bruno González, who holds a PhD in Chemistry from the University of the Republic, is a researcher of non-classical psychedelics, activist, defender of the rights of people who use drugs, and a member of the Imaginario9 collective. He spoke with El Planteo about why this kind of practice is so important.

“As people who use substances ourselves, we know that prohibition and the existence of an unregulated market leave people extremely exposed,” he explained. “When someone accesses a substance, there’s no real certainty about what’s actually in that pill, blotter, or powder. And the first step toward safer use is having more information about its chemical identity.”

No one here is trying to point fingers at people who use drugs. That reality already exists, it’s happening, and trying to push back against a tide that only seems to keep rising is almost unrealistic. Drug checking in spaces where use is highly likely is not a new policy, even if it may sound revolutionary. Just looking at ARDA or PAF! in Argentina, RD in Chile, Soma in Peru, Échele Cabeza in Colombia, Checa tu Sustancia in Mexico, or DanceSafe in the U.S. shows that awareness about what we’re using—and the desire to share information—crosses borders.

“It’s done all over the world; it’s a first step to mitigating the consequences of prohibition,” González explains. He goes on: “But the Imaginario9 collective is about much more than that, because substance testing (which, yes, is very eye-catching) is only part of the work. Many times, it’s the excuse to build closer contact with users, to share experiences, harm-reduction practices, and to talk about pleasure too, because there’s a reason people use drugs in the first place. And I think that’s more valuable than the result alone,” he admits.

What changes from place to place are the model, the scale, and the resources available to these organizations. “Some focus more on communication, others on testing and on-site interventions at parties. We’re in touch with this whole network of allied organizations, especially across Latin America, that regularly attend the Drug Policy Alliance conference,” González adds.

The benefit is clear: reducing the number of intoxications that can end in fatal outcomes. A reality that emerges when people lack quality information about the substances they’re using.

How will the testing work?

To start, testing will take place at parties, as part of an on-site intervention set up within nightlife venues. It’s not just a mobile lab, González explains, but also a kind of “cool-down” or safety space.

“Getting into the technical side, what we do are qualitative analyses,” he says. “That means we can tell people whether their substance is—or isn’t—what they think it is, or whether it contains an adulterant. We run two different tests: a colorimetric test and a thin-layer chromatography analysis. Both require a very small sample, usually a scraping from a pill or a small amount of powder provided by the user.”

For the first test, reagents are used that produce different colors when they come into contact with the substance. At least three different reagents are used for greater reliability, aiming for a clear answer: all or nothing. It either is, or it isn’t.

What this first analysis can’t determine is whether the substance contains “something else,” such as an adulterant. That’s where the second test comes in: thin-layer chromatography, or TLC. This is a separative technique, meaning it allows the different components of a sample to be seen individually. “That’s when we compare it against known adulterant standards and can tell you, for example, whether it’s been cut with caffeine,” the chemist explains.

In short, they can’t yet quantify dosage. The analysis can reliably determine whether, for example, your pill is or isn’t MDMA, or whether it contains something else, but it can’t tell you the dose or how many milligrams are in that pill. “For me, that would be the goal,” González says. “To incorporate a technique that would allow us to provide that kind of information in the future.”

Safeguarding user safety and anonymity

Samples are received at the mobile lab on a voluntary and anonymous basis. “Sometimes we ask basic demographic questions, or whether the person has already ingested part of the substance and what they report about the experience, whether it was bad, whether it matched their expectations, and so on,” the organization explains.

Part of their process involves photographing the substance, which is particularly relevant for pills, as they are often identified by color and logo. From there, analysis reports are produced and published.

There are two main types of publications: one is shared on public-facing social media platforms, made by users, for users, and usually consists of a table with all the analysis data, along with photos of the substances. The other takes the form of a technical report shared through the SAT platform, coordinated with the JND. This latter channel also involves public actors such as healthcare providers (hospitals) that report severe intoxication cases, as well as forensic police and the judicial system when large-scale seizures occur.

The goal is to be clear and straightforward when informing users about what they’re using. In fact, being very clear is part of the strategy. At times, the organization takes information from these technical reports produced by public agencies and translates it into plain language to share among users. “Be aware that this pill triggered an alert because it contained that adulterant,” they offer as an example.

González adds that the purpose of drug checking is to “create strategies to engage with people who use drugs to share reliable information about the harms, risks, and pleasures associated with psychoactive substance use; to advise and guide users about the composition of substances and how different substances interact with the body; and to strengthen people’s decision-making capacity by creating spaces that foster autonomy and collective care.”

Drugs, the State, testing, and desire

Where the State has historically been absent, NGOs, collectives, and grassroots organizations have stepped in and carried the work forward. Today, the Uruguayan government not only recognizes these efforts, but has chosen to work alongside them. Even so, González dreams of a day when his work will be irrelevant.

I hope that one day our testing work won’t be necessary, because there will be a legal market where the drugs people can access come from a system of controlled production and quality that is, so to speak, pharmaceutical,” he says. And that’s where the best results can be achieved: through work that aligns with desire, rather than against it.

The perspective of this collective—and likely many others—is one of Harm Reduction and Pleasure Management (RDGP, by its full name) as it relates to the use of psychoactive substances. It’s not only about minimizing risks or avoiding negative outcomes, but also about acknowledging that drug use exists because it produces pleasure, connection, and meaning, and that denying this dimension only pushes people toward less safe practices.

From this perspective, care does not stand in opposition to enjoyment: it moves alongside it. RDGP seeks to enable more informed, autonomous, and safer experiences, where people can exercise their right to pleasure without being unnecessarily exposed to serious or preventable harm. Within this framework, the role of the State would not be limited to regulation or punishment, but would also include guaranteeing health and care in practices that, even if not always formally legitimized, are part of the social lives of a large portion of the population.

The Uruguayan State, together with the Imaginario9 collective, is not promoting drug use by conducting testing. Drug checking is, rather, a palliative measure, one that emerges as a consequence of prohibitionist, war-on-drugs policies. “What we do need is legitimacy for our work, protection, and clear signals from authorities that what we do is valued and necessary. I believe this new project with the JND is precisely that,” the civil society organization concludes.

<p>The post Government-Led Party Drug-Testing: Inside Uruguay’s No-Penalty Harm Reduction Program first appeared on High Times.</p>



Source link

A man closes his eyes as he smokes a legal cannabis joint

NORML Argues in Supreme Court Brief That Disarming Cannabis Consumers Is Unconstitutional

NORML Argues in Supreme Court Brief That Disarming Cannabis Consumers Is Unconstitutional

A man closes his eyes as he smokes a legal cannabis jointA man closes his eyes as he smokes a legal cannabis joint“The historical analogs the government identifies concern temporary restrictions on carrying or firing weapons while intoxicated or on persons adjudged dangerous — not blanket bans on all users of a disfavored substance.”

The post NORML Argues in Supreme Court Brief That Disarming Cannabis Consumers Is Unconstitutional appeared first on NORML.

Source link

Report: Colorado cannabis vapes show signs of hemp inversion

Report: Colorado cannabis vapes show signs of hemp inversion

Report: Colorado cannabis vapes show signs of hemp inversion

Hemp-derived THC continues to be inverted into Colorado’s legal cannabis market in violation of state law, a recent independent investigation suggests.

Three of 14 cannabis vaporizers purchased at Denver-area legal cannabis stores showed signs of banned hemp-derived cannabinoids in lab tests, The Denver Gazette and ProPublica reported.

ADVERTISEMENT

Colorado’s Marijuana Enforcement Division declined to comment on the results.

Hemp inversion continues in legal cannabis markets, tests show

Complaints of hemp-derived THC produced outside of legal channels appearing on legal store shelves – a practice called “inversion” – have arisen in several states, including New York as well as Colorado.

As MJBizDaily reported last year, Colorado operators have been raising the alarm about hemp THC inversion for more than a year – going

The post Report: Colorado cannabis vapes show signs of hemp inversion appeared first on GrowCola.com.

Source link

How Have Businesses Started Incorporating AI Into Their Companies?

How Have Businesses Started Incorporating AI Into Their Companies?

How Have Businesses Started Incorporating AI Into Their Companies?

In the business world, Artificial Intelligence (AI), or technology that is coded to stimulate human intelligence, is having a major impact on the way which businesses operate. As it is now prevalent in many types of software and applications, AI is revolutionizing workflows, business practices, and entire industries by changing the way businesses work, access information, and analyze data.

There are many ways in which AI tools are used in businesses, but most applications focus on driving growth. Some business benefits of AI include:

  • Boosting efficiency through process automation
  • Improving the speech or consistency of service
  • Using customer insights to inform decision-making
  • Uncovering opportunities for new products

Artificial Intelligence can deliver significant benefits across different departments and business functions.

Improved Customer Engagement and Experience

Chatbots are one of the most common instances of customers directly interacting with AI. Moreover, from a business perspective, chatbots allow companies to streamline their customer service processes, freeing up employees’ time for issues which require more personalized attention. Through sentiment analysis and customer feedback evaluation, AI tools help businesses understand their customers’ needs and preferences, which results in better product development and customer service strategies.

Data Analysis and Insights

Sentiment analysis- otherwise known as emotion AI- is a tactic that companies utilize to gauge the reactions of their customers. Furthermore, AI’s ability to predict consumer behavior can help businesses anticipate future needs and adjust their strategies accordingly. These AI-powered analytical tools’ foresight is crucial for staying ahead of competitors and meeting market demands.

Identifying Fraud

AI algorithms can identify potential risks and fraud through analyzing patterns and irregularities of data in real-time. Specifically, for AI in the financial industry, there are tools available to detect suspicious transactions, by machine learning algorithms. This risk management approach allows businesses to identify cyber-attacks as they happen, reducing the time between threat detection and response.

Optimizing Supply Chain Operations

Artificial Intelligence can have a major impact on operations, in the form of forecasting or as an inventory management tool. AI for supply chain efficiency proves to be useful when allocating resources or people, such as drivers, scheduling processes, and solving or planning around operational disruptions.  AI-driven solutions can assist companies in predicting the price of materials and shipping, estimating how fast products are able to move through the supply chain.

Many successful companies are reaching new heights through integrating AI into current efforts and work, rather than the intention to replace human workers with AI. Through understanding and leveraging AI’s potential, business are able to unlock new levels of success and efficiency.

Sources:

https://www.forbes.com/advisor/business/software/ai-in-business/

https://online.wharton.upenn.edu/blog/how-do-businesses-use-artificial-intelligence/#:~:text=Companies%20today%20have%20access%20to,them%20make%20informed%20business%20decisions.

https://www.investopedia.com/how-ai-is-used-in-business-8611256#:~:text=For%20example%2C%20AI%20can%20be,replace%20human%20labor%20with%20AI:

https://mitsloan.mit.edu/ideas-made-to-matter/how-businesses-can-find-and-prioritize-ai-opportunities

https://business.fiu.edu/academics/graduate/insights/posts/competitive-advantage-of-using-ai-in-business.html

The post How Have Businesses Started Incorporating AI Into Their Companies? appeared first on Connor & Connor PLLC.

Source link